Checkpoint Therapeutics, Inc. (CKPT)
NASDAQ: CKPT · Real-Time Price · USD
4.150
0.00 (0.00%)
At close: May 14, 2025, 4:00 PM
4.160
+0.010 (0.24%)
After-hours: May 14, 2025, 7:39 PM EDT
Checkpoint Therapeutics Stock Forecast
Stock Price Forecast
According to 3 professional analysts, the 12-month price target for Checkpoint Therapeutics stock ranges from a low of $4.10 to a high of $4.80. The average analyst price target of $4.33 forecasts a 4.34% increase in the stock price over the next year.
Price Target: $4.33 (+4.34%)
Analyst Consensus: Buy
* Price targets were last updated on Mar 31, 2025.
Analyst Ratings
The average analyst rating for Checkpoint Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $4.8 | Strong Buy | Maintains | $4.8 | +15.66% | Mar 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $4.1 | Strong Buy → Hold | Downgrades | $4.1 | -1.20% | Mar 11, 2025 |
| Lake Street | Lake Street | Strong Buy → Hold Downgrades $7 → $4.1 | Strong Buy → Hold | Downgrades | $7 → $4.1 | -1.20% | Mar 10, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $9 → $4.8 | Strong Buy | Maintains | $9 → $4.8 | +15.66% | Mar 10, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +116.87% | Jan 13, 2025 |
Financial Forecast
Revenue This Year
41.94M
from 41.00K
Increased by 102,182.93%
Revenue Next Year
189.43M
from 41.94M
Increased by 351.71%
EPS This Year
-0.18
from -1.42
EPS Next Year
1.15
from -0.18
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 76.5M | 195.0M | 960.7M | ||
| Avg | 41.9M | 189.4M | 933.2M | ||
| Low | 9.2M | 182.0M | 896.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 186,409.8% | 365.0% | 407.1% | ||
| Avg | 102,182.9% | 351.7% | 392.6% | ||
| Low | 22,368.3% | 334.0% | 373.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.45 | 1.19 | 6.49 | ||
| Avg | -0.18 | 1.15 | 6.30 | ||
| Low | -0.76 | 1.11 | 6.06 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 463.0% | ||
| Avg | - | - | 446.9% | ||
| Low | - | - | 425.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.